Acute Lymphoblastic Leukemia

Poster: ALL-023

Bone Marrow Fibrosis has a Prognostic Role in Adult Patients with Acute Lymphoblastic Leukemia

Ana Cooke^{1,*}, Daniel Montante-Montes¹, Diego Zúñiga-Tamayo¹, Christianne Bourlon¹, Roberta Demichelis-Gómez¹ ¹ Instituto de Ciencias Medicas y Nutricion Salvador Zubiran, Tlalpan, Mexico City, Mexico

Poster: ALL-039

Obesity and Altered Body Composition in Childhood ALL Survivors

Mohamed Abu El-Asrar Afifi¹, Sara Makkeyah^{1,*}, Marwa El-Sherif¹, Eman Hamama¹ ¹ Ain Shams University, Cairo, Egypt

Poster: ALL-042

Risk Factors and Outcome of Posterior Reversible Encephalopathy Syndrome in Pediatric Cancer Patients

Iman Ragab^{2, *}, Hanafy Hafiz¹, Marwa Shams², Ayda Youssef¹, Saiid Habib² ¹ Children's Cancer Hospital Egypt, Cairo, Egypt, ² Ain Shams University, Pediatric Hematology-Oncology, Cairo, Egypt

Poster: ALL-054

Venous Thrombosis in Children Treated for Acute Lymphoblastic Leukemia on St. Jude Total Therapy Studies Seth Karol^{1,*}, Jeremie Estepp¹, Deqing Pei¹, Cheng Cheng¹, Mary Relling¹, Sima Jeha¹, Ching-Hon Pui¹ St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Poster: ALL-058

Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT) for Standard and High Risk Acute Lymphoblastic Leukemia (ALL) Patients Using Irradiation-Free Conditioning Regimen is Associated with Lower Incidence of Transplant Related Mortality

Gamal M Fathy^{1,*}, Hossam K Mahmoud^{1,2}, Alaa El-Haddad^{1,2}, Omar Fahmy^{1,3}, Raafat Abdelfattah^{1,2}, Mohamed Abdel-Mooti^{1,2}, Mahmoud Bokhary¹, Shaimaa Ibrahim¹

¹ Hematology and Bone Marrow Transplantation Unit, Nasser Institute Hospital for Research and Treatment, Cairo, Egypt, ² Hematology and Bone Marrow Transplantation Unit, National Cancer Institute, Cairo University, Cairo, Egypt, ³ Department of Internal Medicine, KasrAlainy Hospitals, Cairo University, Cairo, Egypt

Poster: ALL-074

Outcome of Acute Lymphoblastic Leukemia (ALL) in Egyptian Children without High Dose Methotrexate: The Pre-Minimal Residual Disease Stratification Era

Iman Ragab ^{1, *}, Sara Makkeyah ¹, Ayat Farouk ¹, Mahmoud Shawiesh ¹Faculty of Medicine, Ain Shams University, Cairo, Egypt

Poster: ALL-089

Age, Disease Status before Blinatumomab, MRD Negativity Obtainment, and Bridge to Transplant Influence Outcome in Patients with B-ALL: A Single Center Experience

*Presenter

Cristina Papayannidis^{1,*}, Stefania Paolini¹, Giovanni Marconi¹, Jacopo Nanni¹, Alessandra Santoro², Valentina Robustelli¹, Maria Chiara Abbenante¹, Chiara Sartor¹, Carolina Terragna¹, Carmen Baldazzi¹, Francesca Volpato¹, Sarah Parisi¹, Luca Bertamini¹, Antonio Curti¹, Giovanni Martinelli^{1, 3} ¹ Institute of Hematology and Medical Oncology "L. and A. Seràgnoli", University of Bologna, Bologna, Italy, ² U.O. Ematologia, Ospedali Riuniti Villa Sofia-Cervello, Palermo, Italy, ³ IRST IRCCS, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy

Poster: ALL-091

Childhood Acute Lymphoblastic Leukemia in Developing Countries, Barriers Against Better Outcome, Single Center Experience, EGYPT Youssef Madney¹, *, Walaa Ahmed¹, Hader Al Mahalway², Emad Abeed¹

¹ Pediatric Oncology, National Cancer Institute, Cairo University, Cairo, Egypt, ² Clinical Microbiology, National Cancer Institute, Cairo University, Cairo, Egypt

Poster: ALL-095

Flow Cytometric DNA Ploidy Detects MRD Hyperdiploid BCP-All Clone

Asish Rath^{1,*}, Nishit Gupta¹, Mayur Parihar², Manish Singh², Sundar Shewale¹, Sambhunath Banerjee¹, Subhajit Brahma¹, Shekhar Krishnan³, Jeevan Kumar⁴, Saurabh Bhave⁴, Vivek Radhakrishnan⁴, Reena Nair⁴, Mammen Chandy⁴, Neeraj Arora¹, Deepak Mishra¹

¹ Department of Laboratory Hematology, Tata Medical Center, Kolkata, West Bengal, India, ² Department of Cytogenetics, Tata Medical Center, Kolkata, West Bengal, India, ³ Department of Pediatric Oncology, Tata Medical Center, Kolkata, West Bengal, India, ⁴ Department of Clinical Hematology, Kolkata, West Bengal, India

Poster: ALL-114

Characterization of PAX5 -Driven Subtypes in B-Progenitor Acute Lymphoblastic Leukemia

Zhaohui Gu^{1,*}, Michelle Churchman¹, Kathryn Roberts¹, Ian Moore¹, Xin Zhou², Joy Nakitandwe¹, Stephane Pelletier³, Sebastien Gingras⁴, Hartmut Berns⁵, Debbie Payne-Turner¹, Ashley Hill¹, Ilaria Iacobucci¹, Kohei Hagiwara², Lei Shi⁶, Deqing Pei⁶, Chunxu Qu¹, Elisabeth Paietta⁷, Ching-Hon Pui⁸, James Downing¹, Mignon Loh⁹, Stephen Hunger¹⁰, Charles Mullighan¹

¹ Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee, United States, ² Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, Tennessee, United States, ³ Department of Immunology, St. Jude Children's Research Hospital, Memphis, Tennessee, United States, ⁴ Department of Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania, United States, ⁵ Department of Transgenic Core Facility, St. Jude Children's Research Hospital, Memphis, Tennessee, United States, ⁶ Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee, United States, ⁷ Cancer Center, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, United States, ⁸ Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, United States, ⁹ Department of Pediatrics, UCSF Benioff Children's Hospital and the Helen Diller Family, San Francisco, California, United States, ¹⁰ Children's Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Poster: ALL-128

KTE-C19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL): Outcomes in Patients Who Were Treated with Prior Blinatumomab in ZUMA-3

Bijal D. Shah^{1,*}, Olalekan O. Oluwole², Maria R. Baer³, Michael R. Bishop⁴, Houston Holmes⁵, Gary J. Schiller⁶, William Donnellan⁷, Kristen M. O'Dwyer⁸, Armen Mardiros⁹, John M. Rossi⁹, Tong Shen⁹, Allen Xue⁹, Rajul K. Jain⁹, Remus Vezan⁹, William G. Wierda¹⁰

¹ Moffitt Cancer Center, Tampa, Florida, United States, ² Vanderbilt-Ingram Cancer Cente, Nashville, Tennessee, United States, ³ University of Maryland, Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States, ⁴ The University of Chicago Medicine, Chicago, Illinois, United States, ⁵ Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States, ⁶ David Geffen School of Medicine at UCLA, Los Angeles, California, United States, ⁷ Sarah Cannon Research Institute, Nashville, Tennessee, United States, ⁸ University of Rochester, Rochester, New York, United States, ⁹ Kite, a Gilead company, Santa Monica, California, United States, ¹⁰ The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Poster: ALL-131

Safety and Efficacy of the BCL Inhibitors Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Andrew Hantel^{1,*}, Joseph Wynne¹, Norman Lacayo², Seong Lin Khaw³, Jeffrey Rubnitz⁴, Charles Mullighan⁴, Michelle Schmidt⁵, Ying Zhou⁵, Jeremy A. Ross⁵, Lindsey Rosenwinkel⁵, Su Young Kim⁵, Elias Jabbour⁶, Thomas Alexander⁷

¹ (Equal contribution) University of Chicago Cancer Research Center, Chicago, Illinois, United States, ² Stanford University, Palo Alto, California, United States, ³ Royal Children's Hospital, Melbourne, Victoria, Australia, ⁴ St. Jude Children's Research Hospital, Memphis, Tennessee, United States, ⁵ AbbVie Inc., North

Chicago, Illinois, United States, ⁶ University of Texas MD Anderson Cancer Center, Houston, Texas, United States, ⁷ University of North Carolina School of Medicine, Chapel Hill, North Carolina, United States Download English Version:

https://daneshyari.com/en/article/8956853

Download Persian Version:

https://daneshyari.com/article/8956853

Daneshyari.com